What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at Lifesci Capital lowered their FY2024 earnings estimates for shares of Viridian Therapeutics in a note issued to investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings per share of ($4.17) for the year, down from their previous forecast of ($4.04). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Lifesci Capital also issued estimates for Viridian Therapeutics’ Q4 2024 earnings at ($1.18) EPS.

Several other equities research analysts also recently commented on VRDN. HC Wainwright increased their price objective on Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a report on Thursday. BTIG Research increased their price objective on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, September 26th. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Viridian Therapeutics in a report on Monday, July 29th. Oppenheimer reissued an “outperform” rating and issued a $28.00 price objective (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a report on Thursday, September 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.33.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $20.14 on Friday. The stock has a market capitalization of $1.60 billion, a P/E ratio of -4.67 and a beta of 1.10. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a 50 day moving average of $22.64 and a 200-day moving average of $16.97.

Insider Transactions at Viridian Therapeutics

In other news, CEO Stephen F. Mahoney bought 21,400 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the acquisition, the chief executive officer now owns 21,400 shares of the company’s stock, valued at $499,262. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Fairmount Funds Management Llc bought 1,600,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the acquisition, the director now directly owns 3,445,813 shares of the company’s stock, valued at approximately $64,608,993.75. This represents a 86.68 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 1,626,400 shares of company stock valued at $30,616,312. 0.65% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Barclays PLC increased its position in shares of Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after purchasing an additional 66,550 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Viridian Therapeutics in the third quarter worth $660,000. Sphera Funds Management LTD. bought a new position in shares of Viridian Therapeutics in the third quarter worth $1,959,000. Point72 Asset Management L.P. bought a new position in shares of Viridian Therapeutics in the third quarter worth $788,000. Finally, Polar Asset Management Partners Inc. increased its position in shares of Viridian Therapeutics by 48.3% in the third quarter. Polar Asset Management Partners Inc. now owns 163,000 shares of the company’s stock worth $3,708,000 after purchasing an additional 53,100 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.